PortfoliosLab logo
AMPH vs. CORT
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between AMPH and CORT is 0.34, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


Performance

AMPH vs. CORT - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Amphastar Pharmaceuticals, Inc. (AMPH) and Corcept Therapeutics Incorporated (CORT). The values are adjusted to include any dividend payments, if applicable.

Loading data...

Key characteristics

Sharpe Ratio

AMPH:

-0.99

CORT:

1.24

Sortino Ratio

AMPH:

-1.38

CORT:

3.64

Omega Ratio

AMPH:

0.83

CORT:

1.50

Calmar Ratio

AMPH:

-0.60

CORT:

3.19

Martin Ratio

AMPH:

-1.26

CORT:

8.12

Ulcer Index

AMPH:

30.84%

CORT:

17.89%

Daily Std Dev

AMPH:

39.69%

CORT:

121.27%

Max Drawdown

AMPH:

-64.63%

CORT:

-94.28%

Current Drawdown

AMPH:

-60.45%

CORT:

-32.10%

Fundamentals

Market Cap

AMPH:

$1.21B

CORT:

$8.24B

EPS

AMPH:

$2.76

CORT:

$1.15

PE Ratio

AMPH:

9.32

CORT:

67.44

PEG Ratio

AMPH:

2.77

CORT:

0.61

PS Ratio

AMPH:

1.66

CORT:

12.03

PB Ratio

AMPH:

1.61

CORT:

12.02

Total Revenue (TTM)

AMPH:

$728.26M

CORT:

$685.45M

Gross Profit (TTM)

AMPH:

$365.89M

CORT:

$674.70M

EBITDA (TTM)

AMPH:

$255.58M

CORT:

$111.33M

Returns By Period

In the year-to-date period, AMPH achieves a -30.76% return, which is significantly lower than CORT's 53.92% return. Over the past 10 years, AMPH has underperformed CORT with an annualized return of 5.00%, while CORT has yielded a comparatively higher 28.58% annualized return.


AMPH

YTD

-30.76%

1M

7.66%

6M

-43.11%

1Y

-39.26%

3Y*

-11.54%

5Y*

6.64%

10Y*

5.00%

CORT

YTD

53.92%

1M

8.51%

6M

34.47%

1Y

157.08%

3Y*

54.97%

5Y*

38.64%

10Y*

28.58%

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Amphastar Pharmaceuticals, Inc.

Corcept Therapeutics Incorporated

Go deeper with the Portfolio Analysis tool — backtest performance, assess risk, compare to benchmarks, and more

Risk-Adjusted Performance

AMPH vs. CORT — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

AMPH
The Risk-Adjusted Performance Rank of AMPH is 99
Overall Rank
The Sharpe Ratio Rank of AMPH is 44
Sharpe Ratio Rank
The Sortino Ratio Rank of AMPH is 77
Sortino Ratio Rank
The Omega Ratio Rank of AMPH is 88
Omega Ratio Rank
The Calmar Ratio Rank of AMPH is 1313
Calmar Ratio Rank
The Martin Ratio Rank of AMPH is 1515
Martin Ratio Rank

CORT
The Risk-Adjusted Performance Rank of CORT is 9494
Overall Rank
The Sharpe Ratio Rank of CORT is 8686
Sharpe Ratio Rank
The Sortino Ratio Rank of CORT is 9797
Sortino Ratio Rank
The Omega Ratio Rank of CORT is 9696
Omega Ratio Rank
The Calmar Ratio Rank of CORT is 9797
Calmar Ratio Rank
The Martin Ratio Rank of CORT is 9292
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

AMPH vs. CORT - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Amphastar Pharmaceuticals, Inc. (AMPH) and Corcept Therapeutics Incorporated (CORT). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


The current AMPH Sharpe Ratio is -0.99, which is lower than the CORT Sharpe Ratio of 1.24. The chart below compares the historical Sharpe Ratios of AMPH and CORT, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Loading data...

Go to the full Sharpe Ratio tool to analyze any stock or portfolio. Customize time frames, set your own risk-free rate, and more

Dividends

AMPH vs. CORT - Dividend Comparison

Neither AMPH nor CORT has paid dividends to shareholders.


Tickers have no history of dividend payments

Drawdowns

AMPH vs. CORT - Drawdown Comparison

The maximum AMPH drawdown since its inception was -64.63%, smaller than the maximum CORT drawdown of -94.28%. Use the drawdown chart below to compare losses from any high point for AMPH and CORT.


Loading data...

Go to the full Drawdowns tool for more analysis options, including inflation-adjusted drawdowns, and more

Volatility

AMPH vs. CORT - Volatility Comparison

Amphastar Pharmaceuticals, Inc. (AMPH) has a higher volatility of 11.45% compared to Corcept Therapeutics Incorporated (CORT) at 9.13%. This indicates that AMPH's price experiences larger fluctuations and is considered to be riskier than CORT based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading data...

Financials

AMPH vs. CORT - Financials Comparison

This section allows you to compare key financial metrics between Amphastar Pharmaceuticals, Inc. and Corcept Therapeutics Incorporated. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


80.00M100.00M120.00M140.00M160.00M180.00M20212022202320242025
170.53M
157.21M
(AMPH) Total Revenue
(CORT) Total Revenue
Values in USD except per share items

AMPH vs. CORT - Profitability Comparison

The chart below illustrates the profitability comparison between Amphastar Pharmaceuticals, Inc. and Corcept Therapeutics Incorporated over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

Gross Margin
Operating Margin
Net Margin
Quarterly
Annual

40.0%50.0%60.0%70.0%80.0%90.0%100.0%20212022202320242025
50.0%
98.5%
(AMPH) Gross Margin
(CORT) Gross Margin
AMPH - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2025, Amphastar Pharmaceuticals, Inc. reported a gross profit of 85.25M and revenue of 170.53M. Therefore, the gross margin over that period was 50.0%.

CORT - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2025, Corcept Therapeutics Incorporated reported a gross profit of 154.81M and revenue of 157.21M. Therefore, the gross margin over that period was 98.5%.

AMPH - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2025, Amphastar Pharmaceuticals, Inc. reported an operating income of 37.29M and revenue of 170.53M, resulting in an operating margin of 21.9%.

CORT - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2025, Corcept Therapeutics Incorporated reported an operating income of 3.42M and revenue of 157.21M, resulting in an operating margin of 2.2%.

AMPH - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2025, Amphastar Pharmaceuticals, Inc. reported a net income of 25.29M and revenue of 170.53M, resulting in a net margin of 14.8%.

CORT - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2025, Corcept Therapeutics Incorporated reported a net income of 20.29M and revenue of 157.21M, resulting in a net margin of 12.9%.